Boston area clinical trial for Dasatinib with F & R

[Guest guest]

Recent research shows that a key enzyme in CLL cells is responsible for cell

survival. This enzyme is called LYN kinase. Laboratory studies show that

inhibition of LYN kinase in CLL cells results in the death of CLL cells.

Dasatinib has the ability to inhibit LYN kinase and, therefore, should have some

effect on CLL cells.

The purpose of this study is to see of the study drug dasatinib, in combination

with fludarabine and rituximab, is safe and effective to use for people with

relapsed or refractory CLL/SLL.

More Info:

http://clinicaltrials.gov/ct2/show/NCT01173679?term=CLL & recr=Open & rcv_d=14